Palisade Bio Inc reports results for the quarter ended in June - Earnings Summary

Palisade Bio

13/08/2024 04:52

* Palisade Bio Inc  PALI.OQ  reported a quarterly adjusted
loss of
$3.32​​ per share for the quarter ended in June, higher than the
same quarter last year, when the company reported EPS of
$-7.95.  The mean expectation of two analysts for the quarter
was for a loss of $2.93 per share. Wall Street expected
results to range from $-3.11 to $-2.75 per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Palisade Bio Inc's reported EPS for the quarter was a loss
of
$3.32​.
    * The company reported a quarterly loss of $4.08 million.
    * Palisade Bio Inc shares had fallen by 20.4% this
quarter and
lost 59.5% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 34.9%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is  "buy."

Wall Street's median 12-month price target for Palisade Bio Inc
is $33.75 
This summary was machine generated from LSEG data August 13 at
03:52 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -2.93          -3.32          Missed
 Mar. 31 2024      -4.80          -4.59          Beat
 Dec. 31 2023      -5.17          -6.45          Missed
 Sep. 30 2023      -5.91          -6.60          Missed